CTOR (Citius Oncology) 3-1 Month Momentum %: -24.80% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.65
! 2 Warning Signs
View Full Analysis

What is Citius Oncology 3-1 Month Momentum %?

Citius Oncology CTOR -4.23% 10 3-1 Month Momentum % is -24.80% as of Jul. 20, 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,019 Drug Manufacturers companies, Citius Oncology ranks worse than 82.24% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-20), Citius Oncology's 3-1 Month Momentum % is -24.80%.

The industry rank for Citius Oncology's 3-1 Month Momentum % or its related term are showing as below:

CTOR's 3-1 Month Momentum % is ranked worse than
82.24% of 1019 companies
in the Drug Manufacturers industry
Industry Median: -10 vs CTOR: -24.80

Citius Oncology  (NAS:CTOR) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Citius Oncology 3-1 Month Momentum % Related Terms

CTOR vs INCR, TLPH, ETST: 3-1 Month Momentum % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology 3-1 Month Momentum % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's 3-1 Month Momentum % falls into.


CTOR
10GF Score
Citius Oncology Inc CTOR
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology  (NAS:CTOR) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -24.80% mean?
Citius Oncology (CTOR) has a 3-1 Month Momentum % of -24.80% as of Jul. 20, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #838 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Citius Oncology's 3-1 Month Momentum % too high?
Citius Oncology's current 3-1 Month Momentum % is -24.80%. Based on the distribution chart, Citius Oncology ranks #838 out of 1019 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's 3-1 Month Momentum % compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #838 out of 1019 companies for 3-1 Month Momentum %. This places Citius Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Citius Oncology and its competitors. Citius Oncology's current 3-1 Month Momentum % is -24.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current 3-1 Month Momentum % of -24.80%. The current 3-1 Month Momentum % is -24.80%. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Citius Oncology (CTOR), the current 3-1 Month Momentum % is -24.80% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price